On Friday, Intellia Therapeutics Inc (NASDAQ: NTLA) was 5.52% up from the session before settling in for the closing price of $8.52. A 52-week range for NTLA has been $5.90 – $28.25.
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.04%. When this article was written, the company’s average yearly earnings per share was at 23.83%. With a float of $109.90 million, this company’s outstanding shares have now reached $115.79 million.
Intellia Therapeutics Inc (NTLA) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Intellia Therapeutics Inc stocks. The insider ownership of Intellia Therapeutics Inc is 5.12%, while institutional ownership is 86.21%. The most recent insider transaction that took place on Oct 01 ’25, was worth 539. In this transaction EVP, Chief Scientific Officer of this company sold 31 shares at a rate of $17.38, taking the stock ownership to the 105,184 shares. Before that another transaction happened on Oct 01 ’25, when Company’s VP, Chief Accounting Officer sold 1,871 for $17.38, making the entire transaction worth $32,518. This insider now owns 55,266 shares in total.
Intellia Therapeutics Inc (NTLA) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -1.27 earnings per share (EPS) during the time that was better than consensus figure (set at -1.32) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.78% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
You can see what Intellia Therapeutics Inc (NTLA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.27, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -3.63 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Looking closely at Intellia Therapeutics Inc (NASDAQ: NTLA), its last 5-days average volume was 4.24 million, which is a drop from its year-to-date volume of 5.18 million. As of the previous 9 days, the stock’s Stochastic %D was 71.01%.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 5.12%, which indicates a significant decrease from 36.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.63 in the past 14 days, which was lower than the 1.10 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.27, while its 200-day Moving Average is $11.45. However, in the short run, Intellia Therapeutics Inc’s stock first resistance to watch stands at $9.22. Second resistance stands at $9.44. The third major resistance level sits at $9.79. If the price goes on to break the first support level at $8.65, it is likely to go to the next support level at $8.30. Now, if the price goes above the second support level, the third support stands at $8.08.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
There are 115,830K outstanding shares of the company, which has a market capitalization of 1.04 billion. As of now, sales total 57,880 K while income totals -519,020 K. Its latest quarter income was 13,780 K while its last quarter net income were -101,320 K.
